Sobi Shares Remain Fairly Valued After Strong 3Q as Competitor Data Approaches
We don’t expect any major changes to our SEK 123 per share fair value estimate for Sobi after a quarter with strong hemophilia performance but lackluster sales from the firm’s partnered portfolio. Total sales grew 37% in the third quarter (41% at constant currency), with Sobi’s launches of hemophilia drugs Elocta and Alprolix continuing to ramp up strongly in Sobi’s territories, while royalties from partner Bioverativ are growing at a slower rate. While management has increased guidance for full...Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.